Merck Plans Phase III Prevymis CMV Trials In Renal Transplant Patients

Merck & Co will start late-stage CMV prevention testing of first-in-class viral terminase complex inhibitor in renal transplant patients during the first half of 2018, following its launch for stem cell transplant recipients.